Hansen Gwenn
SEC CIK 1817160 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | CSO | 118.7K | — | $1.29M | 61 | 2021-07-01 | 2026-09-01 |
Most active insiders at NRIX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Ring Christine | CLO | — | $3.26M |
| 2 | van Houte Hans | CFO | — | $635.3K |
| 3 | Hansen Gwenn | CSO | — | $630.9K |
Transactions 61
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-01 17:19 | 2026-09-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $1.86 | +1,452 | 118.7K | +1% | +$2,701 |
| DT | 2026-09-01 17:19 | 2026-09-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $25.47 | -1,452 | 117.2K | -1% | -$37.0K |
| DT | 2026-08-05 18:59 | 2026-08-05 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $1.86 | +4,356 | 121.6K | +4% | +$8,102 |
| DT | 2026-08-05 18:59 | 2026-08-05 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $25.00 | -4,356 | 117.2K | -4% | -$108.9K |
| MT | 2026-08-05 06:39 | 2026-08-04 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale | $24.36 | -4,111 | 117.2K | -3% | -$100.1K |
| DM | 2026-07-30 17:50 | 2026-07-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +10.2K | 125.2K | +9% | $0 |
| D | 2026-07-30 17:50 | 2026-07-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $23.38 | -3,847 | 121.3K | -3% | -$90.0K |
| T | 2026-06-25 18:49 | 2026-06-25 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale | $20.00 | -5,394 | 115.0K | -4% | -$107.9K |
| DM | 2026-04-30 17:35 | 2026-04-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +8,608 | 123.6K | +7% | $0 |
| D | 2026-04-30 17:35 | 2026-04-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $16.65 | -3,214 | 120.4K | -3% | -$53.5K |
| D | 2026-02-03 | 2026-02-03 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.84 | +31.3K | 115.0K | +37% | +$26.3K |
| DM | 2026-01-30 | 2026-01-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +11.8K | 85.7K | +16% | $0 |
| DM | 2026-01-30 | 2026-01-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $16.60 | -4,895 | 83.8K | -6% | -$81.2K |
| DM | 2025-10-30 | 2025-10-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +11.8K | 74.2K | +19% | $0 |
| D | 2025-10-30 | 2025-10-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $12.80 | -4,087 | 76.8K | -5% | -$52.3K |
| DM | 2025-07-30 | 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +11.8K | 64.7K | +22% | $0 |
| D | 2025-07-30 | 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $12.01 | -4,308 | 69.0K | -6% | -$51.7K |
| DM | 2025-04-30 | 2025-04-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +8,956 | 59.1K | +18% | $0 |
| D | 2025-04-30 | 2025-04-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $11.50 | -3,377 | 61.5K | -5% | -$38.8K |
| DM | 2025-01-30 | 2025-01-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $19.86 | -3,690 | 55.9K | -6% | -$73.3K |
| DM | 2025-01-30 | 2025-01-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +8,957 | 53.9K | +20% | $0 |
| DM | 2024-10-30 | 2024-10-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +8,957 | 50.4K | +22% | $0 |
| D | 2024-10-30 | 2024-10-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $24.31 | -3,437 | 50.7K | -6% | -$83.6K |
| D | 2024-07-30 | 2024-07-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $20.67 | -3,408 | 45.1K | -7% | -$70.4K |
| DM | 2024-07-30 | 2024-07-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +8,957 | 42.8K | +26% | $0 |
| DM | 2024-04-30 | 2024-04-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +5,206 | 41.6K | +14% | $0 |
| D | 2024-04-30 | 2024-04-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $12.04 | -2,007 | 39.6K | -5% | -$24.2K |
| DM | 2024-01-30 | 2024-01-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +5,207 | 36.7K | +17% | $0 |
| D | 2024-01-30 | 2024-01-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $7.99 | -2,334 | 36.4K | -6% | -$18.6K |
| D | 2023-11-01 | 2023-10-31 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $5.20 | -1,633 | 33.5K | -5% | -$8,492 |
| DM | 2023-11-01 | 2023-10-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +5,207 | 33.2K | +19% | $0 |
| DM | 2023-08-01 | 2023-07-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +5,207 | 31.8K | +20% | $0 |
| D | 2023-08-01 | 2023-07-31 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $9.65 | -1,884 | 30.0K | -6% | -$18.2K |
| D | 2023-05-02 | 2023-05-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $9.88 | -1,136 | 26.6K | -4% | -$11.2K |
| D | 2023-05-02 | 2023-04-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +3,206 | 27.8K | +13% | $0 |
| D | 2023-02-01 | 2023-01-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +3,207 | 24.4K | +15% | $0 |
| D | 2023-02-01 | 2023-01-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $11.78 | -1,412 | 23.0K | -6% | -$16.6K |
| D | 2022-11-01 | 2022-10-31 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $12.88 | -1,165 | 21.2K | -5% | -$15.0K |
| D | 2022-11-01 | 2022-10-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +3,207 | 22.4K | +17% | $0 |
| D | 2022-08-02 | 2022-07-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +3,207 | 20.4K | +19% | $0 |
| D | 2022-08-02 | 2022-08-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $15.67 | -1,186 | 19.2K | -6% | -$18.6K |
| D | 2022-05-03 | 2022-05-02 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $11.75 | -1,098 | 17.2K | -6% | -$12.9K |
| D | 2022-05-03 | 2022-04-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $0.00 | +3,206 | 18.2K | +21% | $0 |
| DM | 2022-01-04 | 2022-01-03 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $9.06 | +1,828 | 14.6K | +14% | +$16.6K |
| D | 2022-01-04 | 2022-01-03 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $28.96 | -1,828 | 14.2K | -11% | -$52.9K |
| D | 2021-12-02 | 2021-12-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $7.26 | +400 | 14.6K | +3% | +$2,904 |
| D | 2021-12-02 | 2021-12-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $29.13 | -400 | 14.2K | -3% | -$11.7K |
| D | 2021-11-02 | 2021-11-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $33.24 | -400 | 14.2K | -3% | -$13.3K |
| D | 2021-11-02 | 2021-11-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $7.26 | +400 | 14.6K | +3% | +$2,904 |
| D | 2021-10-28 | 2021-10-27 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $7.26 | +400 | 14.6K | +3% | +$2,904 |
| D | 2021-10-28 | 2021-10-27 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $35.00 | -400 | 14.2K | -3% | -$14.0K |
| D | 2021-10-04 | 2021-10-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $7.26 | +400 | 14.6K | +3% | +$2,904 |
| D | 2021-10-04 | 2021-10-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $29.92 | -400 | 14.2K | -3% | -$12.0K |
| D | 2021-09-08 | 2021-09-07 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $7.26 | +1,600 | 15.8K | +11% | +$11.6K |
| D | 2021-09-08 | 2021-09-07 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $35.00 | -1,600 | 14.2K | -10% | -$56.0K |
| D | 2021-09-02 | 2021-09-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $32.34 | -400 | 14.2K | -3% | -$12.9K |
| D | 2021-09-02 | 2021-09-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $7.26 | +400 | 14.6K | +3% | +$2,904 |
| D | 2021-08-03 | 2021-08-02 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $7.26 | +400 | 14.2K | +3% | +$2,904 |
| D | 2021-08-03 | 2021-08-02 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $31.21 | -400 | 13.8K | -3% | -$12.5K |
| D | 2021-07-02 | 2021-07-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | S - Sale+OE | $26.76 | -400 | 13.8K | -3% | -$10.7K |
| D | 2021-07-02 | 2021-07-01 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | CSO | M - OptEx | $7.26 | +400 | 14.2K | +3% | +$2,904 |
Purchase Sale Sale after option exercise All abbreviations